Frequently Asked Questions

No — and this is a critical point. The pre-dosed auto-injector pen that Eli Lilly will eventually sell commercially does not yet exist as an approved product. However, the molecule itself — retatrutide — can be accessed today through research-grade peptide supply chains, reconstituted with bacteriostatic water, and administered using a standard small-gauge insulin syringe. Tens of thousands of people worldwide already use this method for GLP-1 class peptides. The pen simply makes the process more convenient; it is not a prerequisite.

A reconstituted peptide vial starts as a lyophilised (freeze-dried) powder of retatrutide sealed in a sterile glass vial. Before use, you add a precise amount of bacteriostatic water — a sterile, lightly preserved diluent — which dissolves the powder into a clear solution. You then draw your prescribed dose into an insulin syringe (typically measured in units on the syringe barrel) and inject it subcutaneously. The pen format, by contrast, comes pre-filled and pre-dosed — no mixing required. Clinically, the molecule delivered is identical; only the preparation step differs.

Most people are surprised by how straightforward subcutaneous (under-the-skin) self-injection is. The needle used is extremely fine — a 29–31 gauge, 4–8mm insulin needle — and the injection goes into the soft tissue of the abdomen, thigh, or upper arm. There is minimal discomfort. Millions of people with diabetes self-inject insulin daily using this exact technique. Your prescribing physician or a nurse will walk you through the process during your first consultation, and most patients report feeling confident within their first or second dose.

The recommended needle specification for subcutaneous peptide injection is typically a 29–31 gauge, 4–8mm insulin syringe (often sold as U-100 insulin syringes). The smaller the gauge number, the thicker the needle — so 31 gauge is finer than 29 gauge and causes less discomfort. Your prescribing doctor will advise on the specific syringe and whether to use a 0.3ml, 0.5ml, or 1ml barrel depending on your dose volume. Never use intravenous syringes, which are far larger than required.

Retatrutide is administered subcutaneously — meaning into the fatty tissue just beneath the skin, not into muscle. The three recommended injection sites are: (1) Abdomen — at least 2 inches from the belly button, avoiding the waistband area; (2) Outer thigh — the middle third of the front-outer thigh; (3) Upper arm — the outer, fleshy area. Rotating between sites each week prevents localised skin irritation or lipohypertrophy (a small, lumpy build-up of tissue from repeated injection in one spot). Most people find the abdomen easiest for self-injection.

Your prescribing physician will provide you with a specific dose in milligrams (e.g. 1mg, 4mg, 9mg, 12mg) and tell you the volume of bacteriostatic water to add to your vial. This determines the concentration — for example, mixing 2mg of retatrutide into 2ml of water gives a 1mg/ml solution, meaning a 1mg dose = 1ml = 100 units on a U-100 syringe. Your doctor will provide a simple conversion so you know exactly which syringe line to draw to. Always double-check your dose calculation before injecting, and ask your medical team if anything is unclear.

Before reconstitution (mixing), lyophilised peptide vials are typically stored in the refrigerator (2–8°C / 36–46°F) and should not be frozen. After reconstitution with bacteriostatic water, the solution should be stored in the refrigerator and is typically stable for 28–30 days. Keep vials away from direct light and do not shake the vial vigorously — gently swirl to mix. Once the commercial auto-injector pen becomes available, it will have its own storage guidelines, but refrigeration will similarly be required.

The short answer: barely. The needles used for subcutaneous injection are extremely thin and short — finer than many sewing needles — and the injection goes into soft fatty tissue rather than muscle. Most people describe the sensation as a very brief, mild pinch, often less uncomfortable than a finger-prick blood sugar test. Allowing the solution to warm to room temperature for 5–10 minutes before injecting, and injecting slowly, can further reduce any discomfort.

Retatrutide is a once-weekly injection, administered on the same day each week. This is possible because of the molecule's long pharmacological half-life of approximately 6 days — achieved through its fatty diacid acylation, which allows it to bind reversibly to albumin in the bloodstream and release slowly. If you miss a dose by a day or two, you can take it as soon as you remember; if the next dose is imminent, skip the missed one and resume your normal schedule. Do not double-dose.

TRIUMPH stands for Triple Receptor Agonist Intervention Utilizing Metabolic Pathways in Health. It is Eli Lilly's global Phase 3 registration programme for retatrutide, encompassing 8 major trials across different patient populations: obesity without diabetes (TRIUMPH-1), obesity with Type 2 Diabetes (TRIUMPH-2), obesity with cardiovascular disease (TRIUMPH-3), and obesity with knee osteoarthritis (TRIUMPH-4, already completed). Additional programmes called TRANSCEND (Type 2 Diabetes) and SYNERGY (liver disease/MASLD) run in parallel.

TRIUMPH-4, reported in December 2025, was a 68-week, randomised, double-blind, placebo-controlled trial in 445 adults with obesity and knee osteoarthritis. Key findings: 28.7% mean weight loss at 12mg (vs 2.1% placebo); 100% of 12mg participants achieved at least 5% weight loss; WOMAC knee pain scores reduced by 75.8%; more than 1-in-8 participants became completely free of knee pain; systolic blood pressure reduced by 14 mmHg; and cardiovascular risk markers (triglycerides, non-HDL cholesterol, hsCRP) all significantly reduced.

Bariatric surgery (gastric bypass or sleeve gastrectomy) produces approximately 25–30% weight loss and has been the gold standard for severe obesity for decades. Retatrutide at 28.7% mean weight loss in Phase 3 matches — and in some analyses exceeds — surgical outcomes, without the risks, recovery time, or permanence of an anatomical procedure. This is why researchers describe retatrutide as potentially 'surgical-level' efficacy in a once-weekly injection.

Yes. Phase 2 trials included a diabetic cohort, and the TRIUMPH-2 and TRANSCEND Phase 3 programmes are specifically designed for Type 2 Diabetes populations. Phase 2 data showed: 16.9% mean weight loss in T2D participants at 36 weeks (remarkable for a diabetic population), and HbA1c reduction of 1.6% — a result that meets the threshold for diabetes drug approval on its own. Even in non-diabetics, HbA1c fell by 0.4%, suggesting broad metabolic normalisation.

The results were remarkable. In Phase 2 MASLD (fatty liver disease) substudy data, liver fat was reduced by: 42.9% (1mg dose), 57.0% (4mg), 81.4% (8mg), and 82.4% (12mg) — all at 24 weeks. The placebo arm showed a 0.3% increase in liver fat, confirming the reduction is entirely drug-driven. The dedicated SYNERGY Phase 3 programme will confirm these results in a full MASLD/MASH (metabolic-associated fatty liver disease) trial.

In TRIUMPH-4, retatrutide significantly reduced multiple cardiovascular risk markers: systolic blood pressure fell by 14 mmHg (12mg arm); triglycerides fell ~30%; HDL (good) cholesterol rose ~8%; non-HDL cholesterol was significantly reduced; and high-sensitivity C-reactive protein (hsCRP) — a marker of cardiovascular inflammation — was significantly reduced. The TRIUMPH-3 trial, expected to report in 2026, will specifically evaluate retatrutide in patients with established cardiovascular disease.

Yes. The landmark Phase 2 retatrutide data was published in the New England Journal of Medicine (NEJM) — one of the most prestigious medical journals in the world — in 2023. The MASLD/liver fat data was published in Nature Medicine in 2024. Both publications are publicly available and are cited throughout our science and clinical results pages.

The most common side effects of retatrutide are gastrointestinal (GI) in nature and are consistent with the broader GLP-1 medication class: nausea (most frequent, particularly during dose escalation), vomiting, diarrhoea, and constipation. These effects are generally dose-dependent, most pronounced during the first few weeks of a new dose level, and improve significantly once the body adjusts. A slow, structured dose titration schedule — starting at 1mg and increasing gradually — is the primary strategy for managing GI side effects.

Dysesthesia is an abnormal skin sensation — such as tingling, burning, numbness, or prickling — not caused by direct pressure or injury. In TRIUMPH-4, dysesthesia was reported by 20.9% of participants on the 12mg dose, compared to just 0.7% on placebo — making it a statistically significant and new safety signal for the class. Eli Lilly is actively investigating its mechanism and long-term significance. It was also reported in 8.8% of the 9mg arm. At this stage, it does not appear to be severe or permanent in the trial data, but it contributed to discontinuation rates and is being closely monitored in ongoing trials.

Nausea is the most commonly reported side effect, but 'major problem' is relative. In clinical trials, most participants continued treatment despite nausea because the benefits were significant. The nausea is typically worst during the first 1–4 weeks at each new dose level and improves substantially as the body adapts. Practical strategies that help: eating smaller portions, avoiding high-fat or spicy foods, staying hydrated, injecting in the evening so peak nausea occurs during sleep, and rising slowly through the dose escalation schedule.

GLP-1 receptor agonists as a class (including semaglutide) carry an FDA black box warning for thyroid C-cell tumours based on rodent studies. However, it is important to note: this finding has not been replicated in human studies, and the relevance to humans is debated in the scientific literature. Retatrutide's trials are monitoring for thyroid changes. Until further data is available, retatrutide should be avoided in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Discuss your thyroid history with your physician.

Pancreatitis (inflammation of the pancreas) is a known risk associated with the GLP-1 drug class and is listed as a warning for semaglutide and tirzepatide. Cases have been reported but are rare. Retatrutide's trials monitor for this. Symptoms to watch for include severe, persistent abdominal pain that may radiate to the back. If you experience this, stop treatment and seek medical attention immediately. People with a history of pancreatitis should discuss this with their physician before starting any GLP-1 class medication.

Rapid weight loss through caloric restriction alone does carry a risk of lean muscle loss alongside fat loss. This is one reason why retatrutide's triple-agonist mechanism — particularly the glucagon receptor activation — is valuable: it preferentially targets visceral and adipose fat. Combining retatrutide with adequate dietary protein (aiming for 1.2–1.6g per kg of body weight daily) and resistance exercise is strongly recommended to preserve and even build lean muscle during weight loss. Your prescribing physician can refer you to a dietitian who specialises in GLP-1 supported weight management.

In TRIUMPH-4: 4.0% of the placebo arm discontinued due to adverse events; 12.2% of the 9mg arm discontinued; and 18.2% of the 12mg arm discontinued. While 18.2% is notably higher than placebo, it means the vast majority — over 80% — of participants on the highest dose continued treatment through 68 weeks despite the side effects, which speaks to the perceived benefit-to-risk balance. Most discontinuations were GI-related or related to the dysesthesia signal.

You don't need to follow a rigid diet — and one of retatrutide's most reported benefits is a dramatic reduction in 'food noise' (the constant mental preoccupation with food). Patients consistently report that making healthier choices becomes natural rather than effortful. That said, maximising your results involves supporting the drug's effects: prioritising protein (1.2–1.6g/kg body weight) to preserve muscle, avoiding ultra-processed foods that can trigger GI side effects, and staying well-hydrated. Think of retatrutide as removing the biological barriers to eating well — not as a replacement for nourishing your body.

Exercise is not required to see significant weight loss on retatrutide — the Phase 3 trials achieved 28.7% weight loss without mandating structured exercise. However, resistance training (weight-bearing exercise 2–3x per week) is strongly recommended to preserve and build lean muscle during weight loss, which supports long-term metabolic health and physical function. Cardiovascular exercise compounds the cardiometabolic benefits. Even light walking has meaningful benefits for glucose management and cardiovascular health. Retatrutide often increases energy levels and motivation to move as weight comes off — many patients describe a virtuous cycle.

This is the central ongoing challenge with GLP-1 class medications: obesity is a chronic condition, and like blood pressure medication, the benefits of retatrutide are largely maintained only while taking it. Studies of semaglutide show that two-thirds of weight is regained within one year of stopping. Retatrutide is expected to follow a similar pattern. Eli Lilly is studying maintenance dosing strategies — lower doses after an induction phase — to address this. For many people, retatrutide may need to be a long-term therapy, similar to how statins or blood pressure medications are used indefinitely for chronic conditions.

Most clinical evidence and expert consensus currently suggests that obesity is a chronic, relapsing condition that benefits from long-term medical management — similar to hypertension or high cholesterol. The TRIUMPH trials run for 68–72 weeks, and seven additional readouts in 2026 will include maintenance and durability data. Your individual duration should be determined with your physician based on your weight loss progress, metabolic health improvements, tolerance, and goals. There is no pre-set maximum duration — the goal is sustained, healthy weight management.

Alcohol is not explicitly contraindicated, but it warrants caution for two reasons: First, GLP-1 class medications can increase sensitivity to alcohol for some people, meaning the same amount of alcohol produces a stronger effect — which increases the risk of hypoglycaemia if you also have diabetes. Second, alcohol is calorically dense, nutritionally poor, and can worsen GI side effects. Moderate alcohol consumption (1–2 units occasionally) is unlikely to be a major issue for most people, but excessive drinking is incompatible with the metabolic goals retatrutide supports. Discuss your habits honestly with your physician.

Retatrutide has no major known drug-drug interactions at this stage of research, but several medication categories require attention: Diabetes medications (insulin, sulfonylureas) may need dose reduction as blood sugar improves — hypoglycaemia risk is real. Oral medications with narrow therapeutic windows may be affected by retatrutide's slowing of gastric emptying, altering their absorption rate. Blood pressure medications may need adjustment as BP improves. A full medication review with your prescribing physician is an essential part of the onboarding process.

While significant weight regain is expected after stopping, some benefits appear to persist or at least reset from a lower baseline: improved insulin sensitivity, remodelled fat distribution (particularly reduction of visceral fat), improved liver health, and — for some — sustained behavioural changes around food that developed during treatment. The goal of retatrutide therapy, from a medical standpoint, is not just weight loss but metabolic system reset. Patients who use the treatment period to embed exercise habits and dietary improvements tend to maintain more of their results after stopping.